Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
]
(2016). High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice..
J Diabetes Complications. 30(1), 9-11.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2014). Treating heart failure with preserved ejection fraction: statins could make the difference..
Angiology. 65(4), 328-9.
(2010). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2009). Targeting triglycerides in secondary prevention: should we bother?.
Int J Clin Pract. 63(1), 15-8.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2007). Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2017). The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins..
Curr Pharm Des. 23(10), 1477-1483.
(2005). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2008). Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study..
Curr Med Res Opin. 24(6), 1593-9.
(2012). Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?.
Curr Vasc Pharmacol. 10(3), 374-7.
(2007). Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?.
Expert Opin Pharmacother. 8(5), 529-35.
(2010). Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?.
Curr Vasc Pharmacol. 8(1), 1-4.
(2008). Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2015). Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention..
Curr Med Res Opin. 31(2), 191-5.
(2014). The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!.
Curr Med Res Opin. 30(9), 1701-5.
(2007). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2010). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010). Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?.
Curr Opin Cardiol. 25(4), 406-10.
(2015). Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII..
Curr Vasc Pharmacol. 13(6), 696-8.
(2006). Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2009). The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?.
Hellenic J Cardiol. 50(2), 89-91.
(2014). Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors..
J Diabetes Complications. 28(2), 122-3.
(2010). Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population..
Curr Med Res Opin. 26(3), 713-9.
